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Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation,




The purpose of this study was to investigate the clinical features of epithelial ovarian cancer
(EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain sig-
nificance [VUS], or wild type).
Materials and Methods
We analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation
type and clinical features, including progression-free survival (PFS), overall survival (OS),
and response rate. These characteristics were compared according to BRCA1/2 mutation
status. 
Results
Thirty-seven (37/116, 31.9%) BRCA1/2 mutations were identified (BRCA1, 30; BRCA2, 7).
Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five
patients (5/37, 13.5%). Twenty-five patients had BRCA1/2 VUSs (25/116, 21.6%). Personal
histories of breast cancer were observed in 48.6% of patients with BRCA1/2 mutation
(18/37), 16.0% of patients with BRCA1/2 VUS (4/25), and 7.4% of patients with BRCA wild
type (4/54) (p < 0.001). Patients with BRCA1/2 mutation showed longer OS than those
with BRCA1/2 wild type (p=0.005). No significant differences were detected in PFS, OS, or
response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p=0.772,
p=0.459, and p=0.898, respectively).
Conclusion
Patients with BRCA1/2 mutation had longer OS than those with BRCA1/2 wild type. Patients
with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.
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Introduction
Epit helial ovarian cancer (EOC) remains the gynecological
cancer with the highest mortality because over two-thirds of
patients have advanced disease upon diagnosis [1]. Only 10%
of cases are due to an inherited predisposition, while the 
majority are attributable to alterations in BRCA1 and BRCA2,
which present the strongest risk factors for breast and ovar-
ian cancers [2]. Indeed, studies of lifetime risk of ovarian can-
cer have revealed that it ranges from 39% to 54% in women
identified as having a BRCA1/2 mutation, with lower risk 
associated with BRCA2 mutation than BRCA1 [3].
Most patients with BRCA1/2 mutations have a demonstra-
bly more favorable outcome than those with sporadic ovar-
ian cancers [4,5]. However, the mechanism of this purported
survival advantage conferred by BRCA1/2 mutation is not
entirely clear. Some have speculated that it results from a
greater susceptibility to chemotherapy owing to a signifi-
cantly higher growth fraction in BRCA1/2 -associated malig-
nancies [6]. However, others have not been able to confirm
the significant survival advantage conferred by BRCA1/2
mutations, specifically in terms of long term overall survival
(OS) [7,8]. Indeed, poorer survival for patients with BRCA1/2
mutations has been reported [9,10], although it remains 
unclear why different investigators have noted such varying
effects of BRCA1/2 alterations on survival.
Several previous studies of BRCA1/2 and EOC have been
conducted in Korea, and BRCA1/2 mutations were found in
33% of patients with a strong family history of EOC [11,12].
Possible candidates of a founder mutation in Korea have also
been reported [13]. Moreover, a large, prospective, nation-
wide study of Korean breast cancer patients and their
BRCA1/2 status suggested that BRCA1 mutation has a signif-
icant negative impact on survival [14]. However, only a few
studies have analyzed the effects of BRCA1/2 mutation status
on the clinical prognosis of EOC patients of Asian ethnicity
[15]. Furthermore, clinical features of EOC patients who have
a BRCA1/2 variant of uncertain significance (VUS), which is
a gene mutation that has an unknown effect on protein func-
tion, have not been reported to date [16]. The potential for an
alternate interpretation of a BRCA1/2 VUS over time carries
with it possible disparate clinical implications. Thus, charac-
terization of patients with BRCA1/2 VUS is required for coun-
seling and follow-up.
Therefore, this study was conducted to investigate clinical
features of EOC patients according to BRCA1/2 mutation sta-
tus (BRCA1/2 mutation vs. BRCA1/2 VUS vs. BRCA1/2 wild
type), including survival.
Materials and Methods
1. Patient selection and pathologic review
The study protocol was approved by the Institutional 
Review Board. During the review of medical records, we 
obtained data describing several patient characteristics, 
including age at diagnosis, histologic type, and surgical stage
as classified by the International Federation of Gynecology
and Obstetrics criteria.
A patient selection diagram is shown in Fig. 1. A total of
711 patients were pathologically confirmed to have EOC
from January 1999 to May 2015. Of these, 595 had uninfor-
mative BRCA1/2 mutation statuses and were therefore 
excluded. A BRCA1/2 genetic test was performed for the 
Patients were diagnosed as 
  ovarian carcinoma 
  (1999-2015) (n=711)
Patients underwent 
  BRCA1/2 mutation test (n=116)
BRCA1/2 mutation
  (BRCA1, 30; BRCA2, 7) (n=37)
BRCA1/2 VUS 
  (BRCA1, 16; BRCA2, 10) (n=25)
Wild type (n=54)
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Fig. 1.  Patient selection diagram. VUS, variant of uncertain significance.
remaining 116 patients. A gynecologic oncology team at a
single institute conducted all procedures, and a dedicated 
radiologist at the same institute reviewed all data from 
imaging studies (e.g., magnetic resonance imaging and com-
puted tomography). From 2011, neoadjuvant chemotherapy
followed by interval debulking surgery was introduced in
our institution, and 39 out of the 116 patients received this
treatment. All 116 patients were treated with platinum based
chemotherapy. These patients were analyzed for mutation
type and clinical features including family history, personal
breast cancer history, progression-free survival (PFS), OS,
and response rate. 
The response rate was determined using the Response
Evaluation Criteria in Solid Tumors system. Specifically, we
analyzed PFS and OS in patients with BRCA1/2 mutation and
compared these data with those of patients with BRCA1/2
wild type and VUS. PFS was defined as the period in months
between the dates of diagnosis and relapse or last contact.
OS was defined as the period in months between the dates
of diagnosis and death or last contact. 
2. Direct sequencing
Genetic testing for BRCA1 and BRCA2 (accession numbers
NM_007294 and NM_000059, respectively) mutations was
performed using direct sequencing as previously described
[12]. The genetic mutations analyzed were confined to dele-
terious mutations such as frameshift or nonsense mutations.
Variations were described following the nomenclature sys-
tem of the Human Genome Variation Society (http://www.
Table 1. Patient characteristics
Characteristic Overall BRCA1/2 BRCA1/2 BRCA1/2 p-valuepopulation (n=116) mutation (n=37) VUS (n=25) wild type (n=54)
Age
Mean±SD 52.2±11.4 52.4±9.3 52.0±11.6 52.2±12.8 0.99a)
Stage FIGO
I-II 21 (18.1) 2 (5.4) 6 (24.0) 13 (24.1) 0.059b)
III-IV 94 (81.0) 34 (91.9) 19 (76.0) 41 (75.9)
NI 1 (0.9) 1 (2.7) 0 ( 0 (
Histology
Serous 91 (78.4) 32 (86.5) 18 (72.0) 41 (75.9) 0.198b)
Mucinous 8 (6.9) 0 ( 2 (8.0) 6 (11.1)
Endometrioid 5 (4.3) 0 ( 2 (8.0) 3 (5.6)
Clear cells 5 (4.3) 0 ( 1 (4.0) 4 (7.4)
Others 3 (2.6) 2 (5.4) 1 (4.0) 0 (
NI 4 (3.4) 3 (8.1) 1 (4.0) 0 (
Grade
02-1 45 (38.8) 9 (24.3) 10 (40.0) 26 (48.1) 0.260b)
3 60 (51.7) 23 (62.2) 14 (56.0) 23 (42.6)
NI 11 (9.5) 5 (13.5) 1 (4.0) 5 (9.3)
Optimal surgery
Yes 82 (70.7) 22 (59.5) 20 (80.0) 40 (74.1) 0.130b)
No 22 (19.0) 11 (29.7) 0 ( 11 (20.4)
NI 12 (10.3) 4 (10.8) 5 (20.0) 3 (5.6)
Personal history of breast cancer
Yes 26 (22.4) 18 (48.6) 4 (16.0) 4 (7.4) < 0.001b)
No 89 (76.7) 18 (48.6) 21(84.0) 50 (92.6)
NI 1 (0.9) 1 (2.7) 0 ( 0 (
Family history of breast/ovarian cancer
Yes 47 (40.5) 18 (48.6) 9 (36.0) 20 (37.0) 0.299b)
No 65 (56.0) 16 (43.2) 15 (60.0) 34 (63.0)
NI 4 (3.4) 3 (8.1) 1 (4.0) 0 (
Values are presented as number (%). VUS, variant of uncertain significance; SD, standard deviation; FIGO, International Fed-
eration of Gynecology and Obstetrics; NI, not indicated. a)ANOVA test, b)Chi-square Pearson’s test.
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hgvs.org/mutnomen) and the conventional nomenclature
system from the Breast Cancer Information Core (BIC;
http://research.nhgri.nih.gov/bic/).
3. Statistical analysis
Statistical analysis was performed using IBM SPSS ver.
20.0 (IBM Corp., Armonk, NY). A Kolmogorov-Smirnov test
was used to verify standard normal distributional assump-
tions. Patient clinical features including response rate, PFS,
and OS were analyzed using an ANOVA test, a Pearson’s
chi-squared test, and Kaplan-Meier survival analysis. A 




Patient characteristics are shown in Table 1. Among the
116 EOC patients who underwent BRCA1/2 gene tests by the
polymerase chain reaction–denaturing high performance liq-
uid chromatography–sequencing method, 37 (37/116, 31.9%)
BRCA1/2 mutations were identified (BRCA1, 30; BRCA2, 7).
In addition, 25 patients with BRCA1/2 VUSs were identified
(25/116, 21.6%) and two different types of BRCA1/2 VUS
were found simultaneously in one patient.
No significant differences were detected in terms of mean
age, International Federation of Gynecology and Obstetrics
stage, cancer histology, grade, and performance of optimal
surgery. Personal histories of breast cancer were observed in
48.6% of patients with BRCA1/2 mutation (18/37), 16.0% of
patients with BRCA1/2 VUS (4/25), and 7.4% of those with
wild type (4/54) (p < 0.001). A family history of BRCA1/2-
associated cancer was present in 48.6% of patients with
BRCA1/2 mutation (18/37), 36.0% of those with BRCA1/2
VUS (9/25), and 37% of BRCA1/2 patients with BRCA wild
type (20/54) (p=0.299).
2. Response rates and survival
The response rate was 83.8% in patients with BRCA1/2
mutation (31/37), 88.0% in patients with BRCA1/2 VUS
(22/25), and 85.2% in patients with BRCA1/2 wild type
(46/54). No significant differences were detected between
the three groups (p=0.898) (Table 2).
The median PFS was 17, 14, and 13 months for patients
with BRCA1/2 mutation, VUS, and wild type, respectively.
Patients with BRCA1/2 mutation had longer PFS than those
with BRCA1/2 wild type, although this difference did not
achieve statistical significance (p=0.071). No significant dif-
ferences were detected in terms of PFS between patients with
BRCA1/2 VUS and BRCA1/2 mutation or wild type (p=0.772
and p=0.455, respectively) (Fig. 2).
The median OS was 33, 24, and 17 months in patients with
BRCA1/2 mutation, VUS, and wild type, respectively. 
Patients with BRCA1/2 mutation showed longer OS than
those with BRCA1/2 wild type (p=0.005). No significant dif-
ferences were detected in OS between patients with BRCA1/2
VUS and BRCA1/2 mutation or wild type (p=0.459 and
p=0.211, respectively) (Fig. 3).
3. Frequently observed BRCA1/2 alterations
Frequently observed BRCA1/2 alterations in this study are
presented in Tables 3 and 4. The c.3627_3628insA (p.Leu1209
_Glu1210?fs) alteration in BRCA1 (exon 11) was recurrent in
five patients (5/37, 13.5%). Among the 25 patients with
BRCA1/2 VUS, c.8187G>T (p.Lys2729Asn) mutation in
BRCA2 (exon 18) was present in four (4/25, 16%). All of the
frequently observed alterations were reported in the Breast
Cancer Information Core database. 
Discussion
In the present study, we investigated the impact of
BRCA1/2 mutation status on the clinical features of EOC 
patients. Patients with BRCA1/2 mutation had improved OS
Table 2. Overall response rates after first chemotherapy in BRCA1/2-positive and sporadic epithelial ovarian cancer patients
No. of patients Complete and partial response p-value
BRCA1/2 mutation 37 31 (83.8) 0.898a)
BRCA1/2 VUS 25 22 (88.0)
BRCA1/2 wild type 54 46 (85.2)
Values are presented as number (%). VUS, variant of uncertain significance. a)Chi-square Pearson’s test.
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Table 4. Frequently observed BRCA1/2 VUSs 
Gene Site Mutation Mutation type No. (%) (n=25) BIC data
BRCA2 Exon 18 c.8187G>T (p.Lys2729Asn) Missense 4 (16.0) Yes
BRCA1 Exon 16 c.5339T>C (p.Leu1780Pro) Missense 3 (12.0) Yes
BRCA1 Exon 16 c.4883T>C (p.Met1628Thr) Missense 2 (8.0) Yes















Fig. 2. Progression-free survival (PFS) curves according
to BRCA1/2 mutation status. Median PFS was 17 months
for BRCA1/2 mutation patients, 14 months for BRCA1/2
variant of uncertain significance (VUS) patients, and 13
months for BRCA1/2 wild type patients. A log-rank test 
revealed longer PFS for BRCA1/2 mutation than wild type
patients; however, this was not statistically significant
(p=0.071). No differences were detected between BRCA1/2















Fig. 3. Overall survival (OS) curves according to BRCA1/2
mutation status. Median OS was 33 months for BRCA1/2
mutation patients, 24 months for BRCA1/2 variant of 
uncertain significance (VUS) patients, and 17 months for
BRCA1/2 wild type patients. A log-rank test revealed sig-
nificantly longer OS for BRCA1/2 mutation than wild type
patients (p=0.005). No differences were detected between
BRCA1/2 wild type and VUS (p=0.211) or BRCA1/2 muta-
tion and VUS (p=0.459). 
Table 3. Frequently observed BRCA1/2 mutations 
Gene Site Mutation Mutation type No. (%) (n=37) BIC data
BRCA1 Exon 11 c.3627_3628insA (p.Leu1209_Glu1210?fs) Frameshift 5 (13.5) Yes
BRCA1 Exon 7 c.390C>A (p.Tyr130Ter) Nonsense 3 (8.1) Yes
BRCA1 Exon 10 c.1399A>T (p.Lys467Ter) Nonsense 2 (5.4) Yes
BRCA1 Exon 11 c.4041_4042delAG  (p.Arg1347_Gly1348ArgAsnfs) Frameshift 2 (5.4) Yes
BRCA1 Exon 11 c.3442delG (p.Glu1148Argfs) Frameshift 2 (5.4) Yes
BRCA2 Exon 15 c.7480C>T (p.Arg2494Ter) Nonsense 2 (5.4) Yes
BIC, Breast Cancer Information Core.
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as compared to those with BRCA1/2 wild type. However, no
significant differences in PFS and response rates were 
detected between the groups included in this study. BRCA1/2
mutation and VUS patients had similar prognoses. Greater
sensitivity to platinum-based chemotherapy among patients
with BRCA1/2 mutation was not identified in this study. To
the best of our knowledge, this is the first study that com-
pared the clinical outcomes of EOC patients with BRCA1/2
mutation, VUS, and wild type.
A favorable prognosis for patients with BRCA1/2 mutation
over that of patients with BRCA1/2 wild type was identified
in this study, although no significant difference was detected
in PFS. The underlying mechanism of BRCA1/2 mutation
conferring a favorable prognosis remains unclear. The main
function of BRCA1/2 proteins is to promote DNA double-
strand break repair via homologous recombination. BRCA1
has been implicated in many cellular functions, including
DNA repair, the maintenance of genomic integrity, and cell
cycle checkpoint control [17,18]. The main function of BRCA2
appears to involve interaction with RAD51 during homolo-
gous recombination DNA repair [19]. Cells with mutated
BRCA1/2 proteins may therefore be rendered less capable of
repairing chemotherapy-induced DNA damage, potentially
leading to an improved response to treatment. This is known
as 'synthetic lethality,' i.e., the enhanced lethality of DNA-
damaging agents.
Our data failed to show significantly longer PFS or a better
response rate to chemotherapy in patients with BRCA1/2
mutation over those of patients with BRCA1/2 VUS or wild
type. To explain the discrepancy between our data and those
of prior studies, a more complex model is necessary to clarify
specific mechanisms of BRCA1/2 dysfunction that result in
better outcomes for EOC patients. It is estimated that approx-
imately 50% of sporadic EOCs show BRCA1 or BRCA2 dys-
function through different mechanisms. Tumors that share
molecular features of BRCA1/2-mutant tumors (i.e., BRCA-
ness) could also emerge in this process that affects or is 
affected by normal BRCA1/2 gene function [20,21]. Previous
studies reported that low BRCA1 or BRCA2 expression in
sporadic EOC could confer similar effects on prognosis as
BRCA1 or BRCA2 mutation. Specifically, low BRCA1 expres-
sion measured by reverse transcription polymerase chain 
reaction was shown to be a positive prognostic factor for both
OS and PFS in patients with sporadic EOCs [22]. This finding
indicates that low BRCA1 expression status in sporadic EOC
has a similar impact on prognosis as germline BRCA1/2
mutation. Therefore, if “BRCAness” could be measured
quantitatively in our study, a precise comparison between
“BRCAness” positive and negative groups would possible.
Interpretation of the clinical implications of BRCA1/2 VUS
remains challenging because misperception by a physician
regarding the implications of VUS could lead to inappropri-
ate risk-reducing surgery, neglect, or providing misinforma-
tion to patients. Myriad Genetic Laboratories (Salt Lake City,
UT) reported that about 7% of their molecular diagnoses of
hereditary breast and ovarian cancer are linked to VUSs
[23,24], and these alterations have been identified more com-
monly in African-American than in Hispanic populations
[25,26]. However, few reports have analyzed VUS prevalence
in Asian patients. Additionally, limited information is avail-
able regarding the clinical features of EOC patients with
BRCA1/2 VUS.
Despite the possibility of selection bias, 21.6% of patients
(25/116)  who underwent BRCA1/2 genetic tests were found
to have BRCA1/2 VUS. Among patients with BRCA1/2 VUS,
16% (4/25) had a personal history of double primary breast
cancer and 36% (9/25) had a family history of breast or ovar-
ian cancer in first-degree relatives. One of the VUSs found in
this study (BRCA1 c.5339T>C) is highly suspected to be a
deleterious mutation based on the patients’ family histories
of BRCA1/2-associated cancer, personal histories of breast
cancer, and population frequency.
Identification of founder mutations is required to improve
the quality of genetic counseling. Moreover, using a more
specific approach to molecular testing leads to greater cost-
effectiveness. If we can recognize differences in susceptibility
due to a specific founder mutation, it will be possible to 
define the role of risk reducing surgery. Frequently observed
alterations in this study are presented in Tables 3 and 4. Stud-
ies to identify founder mutations have been conducted in
Asian countries [27], and one report analyzed possible can-
didates of a founder mutation in Korea [13]. However, spe-
cific mutations that account for a high frequency of cases,
such as that observed in the Ashkenazi Jewish population,
have not yet been discovered. The frequently observed
BRCA1/2 alterations found in this study were not identified
in a previous study conducted in Korea. Accordingly, an 
investigation including a larger number of cases must be 
analyzed to provide accurate information regarding the fre-
quency of founder mutations.
It should be noted that this study had several limitations.
Specifically, it included a small number of patients with
BRCA1/2 mutations because of the low rate of genetic testing,
had a retrospective design with the possibility of selection
bias, and a short follow-up period. Moreover, 595 patients
declined BRCA1/2 genetic testing. Conversely, a previous 
report showed few barriers to participating in genetic coun-
seling and BRCA1/2 testing in Western countries, with a test-
ing rate of 81% [28]. The low rate of genetic testing (16.3%,
116/711) in the present study may be the result of low public
awareness regarding its availability. In addition, this study
included patients representative of a cancer center popula-
tion, and all study participants had been affected by EOC.
Thus, our findings may not apply to patients who have not
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had cancer and are undergoing genetic testing due to family
history alone.
Routine tests for BRCA1/2 germline mutation status in 
patients with EOC may be warranted, as it has been demon-
strated that a deficiency in the BRCA1/2 gene confers sub-
stantial sensitivity to a chemotherapeutic agent, namely
poly(ADP-ribose) polymerase-1 (PARP) inhibitor (olaparib)
[29]. Further research is required to determine whether 
application of this agent to EOCs with pathologic BRCA1/2
VUS is beneficial or not. Some patients with BRCA1/2 VUS
may be responsive to treatment with PARP inhibitors, which
results in synthetic lethality of cells that have deficient 
homologous recombination or double-strand DNA repair.
This might improve survival among such patients. Further
prospective cohort studies with longer follow-up periods as
well as “BRCAness” quantification are needed to enable a
precise understanding of the role of BRCAness on the clinical
features of EOC patients.
Conclusion
Our study provides useful data for counseling EOC 
patients with BRCA1/2 mutation, VUS, and wild type. 
Patients with BRCA1/2 mutation had more favorable prog-
nosis, or significantly longer OS than those with BRCA1/2
wild type, while they have similar prognoses as patients with
BRCA1/2 VUS.
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